Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039182 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
A Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00039182 is a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00039182, a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
Study Locations (1)
Texas
- Southwest Oncology Group - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039182
The ClinicalTrials.gov registry entry for NCT00039182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Recurrent Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00039182 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00039182 about?
NCT00039182 is a clinical study titled "Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung". Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
What is the current status of trial NCT00039182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2002-05.
What conditions does trial NCT00039182 study?
This clinical trial studies the following conditions: Recurrent Malignant Mesothelioma, Epithelial Mesothelioma, Sarcomatous Mesothelioma, Advanced Malignant Mesothelioma.
What interventions are being tested in trial NCT00039182?
The interventions under investigation include: laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00039182?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039182 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.